Compared with DPP-4 inhibitor use, GLP-1 RA use was significantly associated with a reduced risk of major adverse cardiovascular events (aHR 0.52, 95% CI 0.46–0.58), including hospitalizations for coronary artery disease (aHR 0.64, 95% CI 0.54–0.75), stroke (aHR 0.48, 95% CI 0.40–0.56), and heart failure (aHR 0.33, 95% CI 0.25–0.42). The gene discussed is GLP1R; the disease is Stroke.